Neomatrix and 4basebio Announce Publication in Journal for ImmunoTherapy of Cancer Demonstrating Potent Personalized Cancer Vaccine Responses Using Synthetic DNA Platform
We are proud to announce the publication of our latest work in the Journal for ImmunoTherapy of Cancer (JITC): “Synthetic DNA vaccine platform elicits potent immunity where electroporated naked-mRNA is non-immunogenic” . ... (read more)

13 March, 2026 - 1st Annual Congress - Italian Society of Liquid Biopsy
The Liquid Biopsy Revolution: Insights from the 1st SIBIL Annual Meeting The 1st Annual Meeting of SIBIL (Società Italiana di Biopsia Liquida) was an extraordinary gathering of experts focused on a single goal: bringing non-invasive, real-time cancer monitoring into standard clinical practice ... (read more)

17 November, 2025 - LSX Investival in London
Today our CEO Luigi Aurisicchio presented NeoMatrix biotech opportunity to a platea of investors at LSX Investival in London. We are IMPD-ready and have planned our first clinical study in NSCLC early next year ... (read more)

17 November, 2025 - Showcase Conference in London
Our CEO Luigi Aurisicchio will be connecting with investors, partners and peers driving breakthroughs in personalized cancer vaccines with neoantigen prediction, synthetic DNA and innovative solutions for cancer patients. ... (read more)

9 November, 2025 - Neomatrix is at SITC 2025 with two selected abstracts
Fabio Palombo , our CSO and Emily Young , director at 4Basebio will be presenting Neomatrix technology for developing personalized cancer vaccines, based on synthetic DNA and a novel heterologous prime/boost modality which includes next generation, targeted LNP ... (read more)

November, 2025 - Innovation day Lazio Life Science
Neomatrix is proud to have been selected among the Lazio 10 top innovators in Life Science with the maximal score! Our CEO Luigi Aurisicchio presented today at Innovation day Lazio Life Science our groundbreaking technology to representatives of Big Pharma, Investors and startuppers. ... (read more)

25 November, 2025 -BIO-EUROPE - Vienna - Austria
We are heading to BioEurope! Join us to learn more about our personalized, synthetic DNA cancer vaccines and groundbreaking technology ... (read more)

25 October, 2025 - NIBIT Translational Science Annual Meeting in Livorno
Today a fantastic talk by our Ilaria Esposito at NIBIT Translational Science Annual Meeting in Livorno, Italy. A great opportunity to share our Science, breakthrough technology ... (read more)

May 28, 2025 - Neomatrix Secures EUR 1.5 Million in Funding to Advance Personalized Cancer Vaccine Development
A stimulating lecture by our CSO Fabio Palombo at the Accademia Medica di Roma about personalized Cancer Vaccines. ... (read more)

November 21, 2024 - Neomatrix Secures EUR 1.5 Million in Funding to Advance Personalized Cancer Vaccine Development
Neomatrix, a pioneering biotech firm, has successfully closed EUR 1.5 million in additional funding led by existing investors 2Invest AG and i2i Capital Limited. This new investment will be crucial in completing the regulatory development for its proprietary personalized cancer vaccines and exploring innovative combination strategies. ... (read more)

8-10 November 2024. Neomatrix presenting a Poster at SITC’s 39th Annual Meeting
the leading member-driven organization focused on cancer immunotherapy. At SITC’s Annual Meeting, international leaders from academia, regulatory and government agencies, as well as industry representatives meet for advancing Cancer Immunotherapies. ... (read more)

4-6 November 2024. Neomatrix at BioEurope in Stockholm as part of the Italian Delegation.
BIO-Europe® celebrates its 30th anniversary in Stockholm, Sweden, on November 4-6, 2024 and brings together over 5,500 delegates ... (read more)

31 October 2024. Our CEO Luigi Aurisicchio will participate as invited Speaker at The World Vaccine Congress Europe in Barcelona
Europe's largest vaccine event. Together with Big Players and other companies active in the space of personalized cancer vaccine, we will share our approach and breakthrough technology to help patients and treat cancer ... (read more)

9 October 2024. Neomatrix selected as presenting company at BioInItaly
hosted at CPHI Milan. BioInItaly brings together Corporate Venture Capitalists and Business Developers of biopharmaceuticals and biodiagnostics and, on the other, Start-ups and innovative ... (read more)

3-6 June 2024. We are attending the BIO in San Diego, California.
If you want to learn more about Neomatrix unique technology and join us in the development of next generation Cancer Vaccines ... (read more)

3 April 2024. Neomatrix presenting at World Vaccine Congress in Washington DC. A great opportunity to meet old friends and start new collaborations.
This is the momentum for genetic technologies and Personalized Cancer Vaccines. ... (read more)

12 February 2024. Neomatrix was granted 258.751,70 for a Research Project on Breast Cancer.
VAP (Vaccine Ad Personam) aims to establish a new therapy based on Neomatrix technology in the context of breast cancer. In order to understand the feasibility of this innovative therapeutic approach, Neomatrix has entered into collaboration with Professor Silvia Piconese to perform molecular and immunological characterizations in the complex context of breast cancer ... (read more)

November 21, 2023. Neomatrix secures a 1 million non-dilutive grant from Lazio Innova.
4Immunogenomics aims to develop a vaccine based on synthetic DNA that incorporates liquid biopsy in the algorithm for predicting tumor targets. The main objectives of the project are two ... (read more)

June 5, 2023 - NEOMATRIX CONCLUDES SUCCESSFUL FUNDRAISING TO SUPPORT DISCOVERY AND DEVELOMENT OF PERSONALIZED CANCER VACCINES.
The biotech Neomatrix today announced that it has closed a seed funding of EUR 2 millions led by 2Invest AG and i2i Capital Limited. The funds will be used to support discovery and development of personalized cancer vaccines based on innovative DNA technology ... (read more)

May 25, 2023 - 4basebio and Neomatrix announce clinical material supply agreement to develop personalised cancer therapy utilising 4basebio’s proprietary hpDNA™.
Cambridge, UK , 25 May 2023 – 4basebio PLC (AIM: 4BB), an innovation driven biotechnology company enabling and accelerating development of advanced therapy medicinal products (ATMPs) through its high performant synthetic DNA products ... (read more)

April 8, 2021 - Neomatrix awarded at BioinItaly Investment Forum.
Neomatrix awarded at BioinItaly Investment Forum
Neomatrix was among the four start-ups awarded at the “BioinItaly Investement Forum & Intesa San Paolo start up initiative” in the Life Sciences sector, with a novel personalized approach to ... (read more)